89 results
8-K
EX-99
INVA
Innoviva Inc
8 Nov 05
Entry into a Material Definitive Agreement
12:00am
addition to Astellas' pipeline and provides us with the opportunity to deepen our commitment to the treatment of infectious disease, a core focus … , a worldwide infrastructure and a commitment to global growth. With Theravance, they are committed to collaborate for the further development
8-K
EX-99.1
INVA
Innoviva Inc
10 Apr 17
Innoviva Announces $50 Million Partial Royalty Notes Redemption
12:00am
commitment to return capital to its investors and optimize its capital structure. Since the first quarter of 2015, the Company has returned more than $210 … Royalty Notes further illustrates our commitment to returning capital to investors and reducing leverage and interest costs for Innoviva. All
8-K/A
EX-99.1
INVA
Innoviva Inc
2 Dec 11
Other Events
12:00am
, including current batches of VIBATIV.
Based on this information and our ongoing commitment to patient safety, Astellas Pharma US, Inc. made a decision
8-K/A
EX-99.2
INVA
Innoviva Inc
2 Dec 11
Other Events
12:00am
within expiry, including current batches of VIBATIV.
Based on this information and our ongoing commitment to patient safety, Astellas Pharma US, Inc. has
DEFA14A
INVA
Innoviva Inc
5 May 21
Additional proxy soliciting materials
4:17pm
commitment to providing its stockholders a meaningful opportunity to engage with directors and management at the 2021 Annual Meeting and provides
8-K
EX-99.2
krc7w2722jsr 436
23 May 18
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.2
wsiq2w pej9aapb
20 Jan 10
Regulation FD Disclosure
12:00am
8-K
EX-99.1
c0iz3lncj8bmwjyxzn
28 Apr 23
Innoviva Announces Retirement of Board Chairman
8:30pm
8-K
EX-99.1
22z9n3m57w5
6 Jan 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
su561m2p ckb
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
8-K
EX-99.2
vx9zc39ldu
26 May 20
Departure of Directors or Certain Officers
5:14pm
CORRESP
5eqs7vdp045a8nd fvx
5 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99
63bvmvz7fxb90 c1
18 Jul 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
oadvu1de49vf2gi
2 Dec 08
Initial results demonstrate potential of ‘444 in the treatment of patients with moderate to severe asthma
12:00am
DEFA14A
vzgav6oyf3ro434iodgu
28 Apr 23
Additional proxy soliciting materials
8:38pm
8-K
EX-99
t6u pdo5bz806ll0uib8
3 Feb 11
Other Events
12:00am
8-K
EX-99
4nuv4gjwx
27 Oct 09
Regulation FD Disclosure
12:00am
8-K
EX-99.2
3cr9uzho
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
SC TO-C
EX-99.1
ecdl5oszynklul8y0p
11 Jul 22
Information about tender offer
3:46pm
SC TO-C
EX-99.3
z8bdzuii3edd8t
23 May 22
Information about tender offer
8:54pm